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INTRODUCTION
The skin and underlying soft tissues are frequent sites of bacterial infection and one of the most common reasons for administering antibiotic therapy. Skin and skin structure infections (SSSIs) range from relatively benign, uncomplicated conditions (e.g., carbuncles, impetigo) to complicated SSSIs [cSSSIs, e.g., major abscesses, traumatic wounds, and diabetic foot infections (DFI)]. cSSSIs are generally distinguished from uncomplicated SSSIs by the need for surgical debridement and drainage in addition to antibiotic treatment [1] .
At their most severe, cSSSIs can include potentially limb-or life-threatening infections such as necrotizing fasciitis. Consequently, the management of cSSSIs is complex with the need for additional surgery, adequate treatment of comorbidities, antibiotic therapy, prolonged hospitalization, and lengthy convalescence [2] [3] [4] [5] .
The etiology in most cases is bacterial prompting for empirical intravenous (IV) antibiotic therapy against the most likely causative pathogens [6] . In the most serious cases, patients may also need fluid resuscitation and organ support, along with revascularization or limb amputation if severe ischemia is present [6] . Underlying conditions such as diabetes, peripheral vascular disease, chronic venous insufficiency, and compromised immune systems may complicate or curb the response to antibiotic therapy [1, 6] ; management of such conditions must, therefore, be addressed in the course of treatment.
Both Gram-positive bacteria and Gramnegative bacteria are implicated in cSSSIs. Staphylococcus aureus is the most frequently isolated Gram-positive pathogen and the most common cause of cSSSIs [4, 7] , although bhemolytic streptococci are also common and are often associated with rapidly spreading infections such as erysipelas or cellulitis [1] .
Pseudomonas aeruginosa and Escherichia coli are the most frequently isolated Gram-negative bacteria in cSSSIs [7] . Mixed infections are common, especially in patients with major abscesses and DFI, where staphylococci, streptococci, Enterobacteriaceae, and Gramnegative anaerobes, such as Bacteroides spp., may be isolated [8] .
The antibiotic recommendations in guidelines reflect the diverse nature and etiology of bacterial infections of the skin and skin structures [1, [9] [10] [11] [12] [13] . Where infection is likely to be polymicrobial (e.g., DFI or infection of the pelvis and perianal region), broadspectrum antibiotic coverage is warranted.
Although beta-lactams have traditionally been the mainstay of broad-spectrum therapy, fluoroquinolones with enhanced Gram-positive Adv Ther (2013) 30:630-643 631 activity are increasingly used as first-line agents in these cases [14] .
Moxifloxacin (Avelox Ò , Bayer Pharma AG, Leverkusen, Germany) is a broad-spectrum fluoroquinolone possessing greater in vitro activity against Gram-positive aerobic pathogens than earlier fluoroquinolones (e.g., ciprofloxacin) and it also has potent activity against Gram-negative bacteria [15] . Additional activity against anaerobes makes moxifloxacin particularly useful for infections of mixed aerobic and anaerobic etiology [14] .
Moxifloxacin achieves good penetration into muscle, subcutaneous adipose tissue, and inflammatory blister fluid, suggesting that adequate tissue concentrations can be achieved in cSSSIs [15] . Evidence for its clinical efficacy in cSSSIs has been demonstrated in a series of randomized, Phase III controlled trials [16] [17] [18] .
Here we report the results of the Avelox in Routine Treatment of cSSSIs (ARTOS) study, which aimed at obtaining data first, on the characteristics of patients treated with moxifloxacin in a large cohort of patients coming from various geographic regions and second, on the effectiveness, safety, and tolerability of moxifloxacin under daily life treatment conditions in patients with cSSSIs.
METHODS

Study Design
ARTOS was an international, prospective, noninterventional, non-controlled observational study carried out between 2005 and 2009 in hospitalized patients or in outpatients under real-life conditions requiring initial IV antibiotic therapy for cSSSIs. The study was conducted at more than 600 investigational sites across Europe, the Middle East, and Asia-Pacific region.
Study investigators could enroll any patient with a diagnosis of cSSSI, for whom the treating physician had decided to begin moxifloxacin therapy in accordance with its approved indications and according to local guidelines before inclusion into, and independent of, the study. Diagnosis of cSSSI was made at the discretion of the clinician, and it was assumed that most clinical conditions would include skin abscess, post-surgical, or post-traumatic wound infection, bite wound infection, erysipelas/cellulitis, or DFI. Lesion size and level of tissue involvement (epidermis, dermis, fascia, fat, muscle, and bone) were recorded, as well as co-morbidities, risk factors, and details on any surgical intervention.
The study was conducted in accordance with the guidelines of the European Medicines Agency [19] as well as applicable laws and regulations. Where required and before the start of the study, notification and/or approval of the protocol was also obtained from the relevant local competent authorities, ethics committees and/or institutional review boards in each country. Patients gave written informed consent if it was required by local law at the time of study start before documentation of effectiveness and safety findings.
Treatment Schedule and Assessments
The study protocol defined that moxifloxacin should be administered in accordance with the recommendations prevailing at the time of the study and specified in the summary of product characteristics for each country. In Europe, for example, the recommended dosage and treatment duration is a once-daily 400 mg IV infusion of moxifloxacin with a switch to 400 mg per os (PO) at approximately 6 days in a course lasting from 7 to 21 days [20] . 
Data Analyses
The ARTOS study enrolled a total 6,594 patients, of whom 5,444 had data available for safety and effectiveness analysis. Analyses, all of which were descriptive and not subject to formal statistical testing, were based on the analyzed population of 5,444 patients. This included all patients diagnosed with cSSSI and who had received at least one dose of moxifloxacin during the observational period. Of the 467 patients excluded from the analyzed population, the majority (n = 345) did not have an established diagnosis of cSSSI. Patients who received moxifloxacin exclusively orally (n = 683) were also excluded from the analysis as initial oral administration of moxifloxacin is not approved in the label for cSSSIs. Other reasons for exclusion included retrospective documentation, in which the initial visit or all visits had occurred more than 2 days before the actual start of study or after the official study end, lack of symptom documentation at the initial visit, no record of intake or assessment of response to moxifloxacin, and lost to follow-up. Patients' demographic parameters and their medical history are summarized in Table 1 . More male patients than females were enrolled; the mean age was 55.6 ± 17.9 years. Comorbidity was common amongst the study population, with 3,917 (72.0%) patients having at least one concurrent disease or disorder. Cardiac and vascular diseases were the most common comorbidities, followed by endocrine and metabolic disorders (Table 1) . Among risk factors known to predispose to cSSSI, diabetes mellitus was documented most frequently followed by peripheral vascular disease ( Previous antibiotic therapy, 
RESULTS
Patients
n (%)
Treatment
Of the 5,444 patients, 4,692 (86.2%) received sequential IV followed by PO moxifloxacin.
This was administered for an average [mean ± standard deviation (SD)] of 10.6 ± 4.6 days (median 10.0 days) ( Table 4 ).
The IV antibiotic therapy was switched to PO therapy after an average of 3.4 ± 2.5 days in these patients (median 3 days). Of the 752 (13.8%) patients who received moxifloxacin exclusively via the IV route, treatment was maintained for an average of 7.5 ± 4.2 days (median 6.0 days). While patients with posttraumatic wounds, infected ulcers, and DFI required the longest period of treatment, those patients with skin abscesses and bite wounds had the shortest courses of treatment (Table 4) (0.7%) patients. There were no marked regional differences in the percentage of patients (Table 5 ). In general, effectiveness ratings were higher for younger patients than for older ones and for those with mild and moderate infections in comparison with those with severe infections.
Safety and Tolerability
AEs were documented in 144 patients (2.6%), with 110 (2.0%) of these identified as adverse drug reactions (ADRs). Serious AEs were documented in 0.5% and serious ADRs in \0.2% of patients (Table 6 ). AEs led to permanent discontinuation of treatment in 55 patients, which was attributed to an ADR in 46 Adverse central nervous system events such as headache and dizziness were the next most frequent, affecting 10 (0.18%) and 8 (0.15%) patients, respectively. In the majority of patients these ADRs had either resolved or improved by the end of the observation period.
DISCUSSION
ARTOS was an international, prospective, noninterventional, non-controlled observational cohort study in patients with cSSSIs.
Observational studies differ from randomized controlled trials (RCTs) in that a RCT can study the effect of a new intervention on pre-defined parameters in a random sample of well-selected study subjects, whereas observational studies simply observe the effect of the treatment on a broader population [21] . Consequently, RCTs are considered the gold standard for determining causality between the intervention and clinical efficacy. Observational studies can still provide valuable information relevant to real-world settings about the use of a medication in routine clinical practice (e.g., characteristics of patients who receive this medication) and also in countries which in general are not involved in clinical development programs (e.g., the Middle East). In addition, these Phase IV studies are requested by regulatory authorities [22] . In the ARTOS study, for example, patients had participated who would not ordinarily have been enrolled in a randomized controlled trial because of significant comorbidity, and the extent and nature of their cSSSIs (e.g., patients
with necrotizing fasciitis).
In this study, the most frequently diagnosed cSSSIs were post-surgical wound infections, skin abscesses, and DFI. When considering the new Food and Drug Administration diagnostic criteria applied for enrollment into acute bacterial skin and skin structure infection clinical studies [23] , many of the patients enrolled into the ARTOS study had signs and symptoms of a severe infection. Thus, almost half of the erysipelas patients had erythema, edema, and induration of C75 cm 2 (and a systemic sign such as fever C38°C).
Furthermore, approximately 70% of patients with a wound infection had purulent discharge, erythema, edema, and an induration of C75 cm 2 with systemic sign, such as fever C38°C. Frequencies varied between regions, with skin abscesses notably prevalent among patients in the Middle East. Peripheral neuropathy (*65%) and peripheral vascular disease (*55%) affected almost two-thirds and more than a half of all patients with DFI, and osteomyelitis was present in nearly 30% of these patients. The ARTOS study also revealed that diabetes was often poorly controlled or managed as both HbA1c values and fasting blood glucose levels were higher than the respective target values (e.g., 6.5% and 7 mM, respectively) in [60% of these patients.
The increased susceptibility to more severe infections among patients with significant comorbidities (e.g., diabetes) or elderly patients is reflected in this study population, who were also likely to receive a prior course of antibiotic (approximately 40% of patients) for When comorbidities were taken into account regarding DFI patients, which may influence the length of therapy and clinical outcome, we have observed a similar result to that for the DFI patients enrolled in the RELIEF trial which was a randomized, double-blind study [18, 24] Across the three geographical regions, the majority of the patients were treated with sequential IV/PO moxifloxacin 400 mg, switching them from IV to PO therapy after an average of 3-4 days. On average, sequential therapy was administered for about 10 days. However, treatment durations of 14 days is required commonly [24, 25] .
Consistent with the results from the earlier trials, moxifloxacin was generally well tolerated by patients in this study. In fact, the frequency of AEs, ADRs, and deaths was lower in the ARTOS study than those reported in the RCTs, as were rates of permanent discontinuation of therapy. A unique feature of large, noninterventional studies is that they allow for the identification of rare safety events that would not be seen in smaller patient populations in RCTs. In this respect, no unexpected safety events were seen in the ARTOS study. The nature of AEs, including serious AEs, was consistent with the established safety profile of moxifloxacin as described recently [26] .
Observational studies, in addition to the strengths as described earlier, also have a number of limitations. For example, in the ARTOS study the lack of centralized diagnostic criteria or stratification by disease severity was one of the limitations. Interpretation and analysis of observational studies is somewhat difficult due to the heterogeneity of patients in real-life settings. Other limitations were the lack of active comparator and microbiological data; 
